Targeting Aβ and tau in Alzheimer's disease, an early interim report

The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics

Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864 · see citing works

Alzheimer's disease: the amyloid cascade hypothesis

Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · see citing works

Alzheimer's Disease: Genes, Proteins, and Therapy

Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063 · see citing works

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B

Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496 · see citing works

Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685 · see citing works

Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17

Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498 · see citing works

Neurodegenerative Tauopathies

Lee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480 · see citing works

A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain

De Strooper, B., Annaert, W., Cupers, P., Saftig, P., Craessaerts, K., Mumm, J. S., Schroeter, E. H., Schrijvers, V., Wolfe, M. S., Ray, W. J., et al. (1999) · Nature · doi:10.1038/19083 · Cited by 2,100 · see citing works

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065 · see citing works

The carboxy terminus of the .beta. amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease

Jarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022 · see citing works

Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function

SantaCruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., et al. (2005) · Science · doi:10.1126/science.1113694 · Cited by 2,014 · see citing works

Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model

Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892 · see citing works

Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers

Laurén, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W., & Strittmatter, S. M. (2009) · Nature · doi:10.1038/nature07761 · Cited by 1,560 · see citing works

Mutation in the tau gene in familial multiple system tauopathy with presenile dementia

Spillantini, M. G., Murrell, J. R., Goedert, M., Farlow, M. R., Klug, A., & Ghetti, B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7737 · Cited by 1,474 · see citing works

An english translation of alzheimer’s 1907 paper, “über eine eigenartige erkankung der hirnrinde”

Stelzmann, R. A., Norman Schnitzlein, H., & Reed Murtagh, F. (1995) · Clinical Anatomy · doi:10.1002/ca.980080612 · Cited by 1,455 · see citing works

1,026 Experimental treatments in acute stroke

O’Collins, V. E., Macleod, M. R., Donnan, G. A., Horky, L. L., van der Worp, H. B., & Howells, D. W. (2006) · Annals of Neurology · doi:10.1002/ana.20741 · Cited by 1,453 · see citing works

Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416 · cited 1× · see citing works

Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report

Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397 · see citing works

A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity

Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., et al. (2001) · Nature · doi:10.1038/35102591 · Cited by 1,388 · see citing works

Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein

Lewis, J., McGowan, E., Rockwood, J., Melrose, H., Nacharaju, P., Van Slegtenhorst, M., Gwinn-Hardy, K., Murphy, M. P., Baker, M., Yu, X., et al. (2000) · Nature Genetics · doi:10.1038/78078 · Cited by 1,371 · see citing works

Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization

Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073623.84147.a8 · Cited by 1,356 · see citing works

Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial

Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329 · see citing works

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ ₄₂ in humans

Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246 · see citing works

Ways toward an early diagnosis in Alzheimer’s disease: the Alzheimer’s Disease Neuroimaging Initiative (ADNI)

Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C. R., Jagust, W., Trojanowski, J. Q., Toga, A. W., & Beckett, L. (2005) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2005.06.003 · Cited by 1,233 · see citing works

Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease

Walsh, D. M., & Selkoe, D. J. (2004) · Neuron · doi:10.1016/j.neuron.2004.09.010 · Cited by 1,207 · see citing works

GSK-3α regulates production of Alzheimer's disease amyloid-β peptides

Phiel, C. J., Wilson, C., Lee, V. M. ‐., & Klein, P. S. (2003) · Nature · doi:10.1038/nature01640 · Cited by 1,200 · see citing works

Tau proteins of alzheimer paired helical filaments: Abnormal phosphorylation of all six brain isoforms

Goedert, M., Spillantini, M. G., Cairns, N. J., & Crowther, R. A. (1992) · Neuron · doi:10.1016/0896-6273(92)90117-v · Cited by 1,114 · see citing works

Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease

Jack, C. R., Lowe, V. J., Weigand, S. D., Wiste, H. J., Senjem, M. L., Knopman, D. S., Shiung, M. M., Gunter, J. L., Boeve, B. F., Kemp, B. J., et al. (2009) · Brain · doi:10.1093/brain/awp062 · Cited by 1,099 · see citing works

Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo

Fassbender, K. C., Simons, M., Bergmann, C., Stroick, M., Lütjohann, D., Keller, P., Runz, H., Kühl, S., Bertsch, T., von Bergmann, K., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081620098 · Cited by 1,078 · see citing works

Frequent amyloid deposition without significant cognitive impairment among the elderly

Aizenstein, H. J., Nebes, R. D., Saxton, J. A., Price, J. C., Mathis, C. A., Tsopelas, N. D., Ziolko, S. K., James, J. A., Snitz, B. E., Houck, P. R., et al. (2008) · Archives of Neurology · doi:10.1001/archneur.65.11.1509 · Cited by 1,059 · see citing works

Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model

Dodart, J.-C., Bales, K. R., Gannon, K. S., Greene, S. J., DeMattos, R. B., Mathis, C., DeLong, C. A., Wu, S., Wu, X., Holtzman, D. M., et al. (2002) · Nature Neuroscience · doi:10.1038/nn842 · Cited by 858 · see citing works

β-Amyloid1–42 Binds to α7 Nicotinic Acetylcholine Receptor with High Affinity

Wang, H.-Y., Lee, D. H. S., D’Andrea, M. R., Peterson, P. A., Shank, R. P., & Reitz, A. B. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.8.5626 · Cited by 818 · see citing works

BACE1 is the major β-secretase for generation of Aβ peptides by neurons

Cai, H., Wang, Y.-S., McCarthy, D., Wen, H., Borchelt, D., Price, D. L., & Wong, P. (2001) · Nature Neuroscience · doi:10.1038/85064 · Cited by 791 · see citing works

Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease

Reiman, E. M., Chen, K., Liu, X., Bandy, D., Yu, M., Lee, W., Ayutyanont, N., Keppler, J., Reeder, S. A., Langbaum, J. B. S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900345106 · Cited by 785 · see citing works

Aβ Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated Tau Aggregates via the Proteasome

Oddo, S., Billings, L., Kesslak, J. P., Cribbs, D. H., & LaFerla, F. M. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.003 · Cited by 780 · see citing works

Altered microtubule organization in small-calibre axons of mice lacking tau protein

Harada, A., Oguchi, K., Okabe, S., Kuno, J., Terada, S., Ohshima, T., Sato-Yoshitake, R., Takei, Y., Noda, T., & Hirokawa, N. (1994) · Nature · doi:10.1038/369488a0 · Cited by 757 · see citing works

CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation

Petrucelli, L. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh083 · Cited by 735 · see citing works

Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial

Lannfelt, L., Blennow, K., Zetterberg, H., Batsman, S., Ames, D., Harrison, J., Masters, C. L., Targum, S., Bush, A. I., Murdoch, R., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70167-4 · Cited by 725 · see citing works

The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein

Lu, P.-J., Wulf, G., Zhou, X. Z., Davies, P., & Lu, K. P. (1999) · Nature · doi:10.1038/21650 · Cited by 721 · see citing works

Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration <i>in vivo</i>

Noble, W., Planel, E., Zehr, C., Olm, V., Meyerson, J., Suleman, F., Gaynor, K., Wang, L., LaFrancois, J., Feinstein, B., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500466102 · Cited by 709 · see citing works

Control of Peripheral Nerve Myelination by the ß-Secretase BACE1

Willem, M., Garratt, A. N., Novak, B., Citron, M., Kaufmann, S., Rittger, A., DeStrooper, B., Saftig, P., Birchmeier, C., & Haass, C. (2006) · Science · doi:10.1126/science.1132341 · Cited by 703 · see citing works

Episodic memory loss is related to hippocampal-mediated -amyloid deposition in elderly subjects

Mormino, E. C., Kluth, J. T., Madison, C. M., Rabinovici, G. D., Baker, S. L., Miller, B. L., Koeppe, R. A., Mathis, C. A., Weiner, M. W., Jagust, W. J., et al. (2009) · Brain · doi:10.1093/brain/awn320 · Cited by 684 · see citing works

Rapid Restoration of Cognition in Alzheimer's Transgenic Mice with 8-Hydroxy Quinoline Analogs Is Associated with Decreased Interstitial Aβ

Adlard, P. A., Cherny, R. A., Finkelstein, D. I., Gautier, E., Robb, E., Cortes, M., Volitakis, I., Liu, X., Smith, J. P., Perez, K., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.018 · Cited by 672 · see citing works

The high-affinity HSP90–CHIP complex recognizes and selectively degrades phosphorylated tau client proteins

Dickey, C. A., Kamal, A., Lundgren, K., Klosak, N., Bailey, R. M., Dunmore, J., Ash, P., Shoraka, S., Zlatkovic, J., Eckman, C. B., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29715 · Cited by 642 · see citing works

NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo

Eriksen, J. L., Sagi, S. A., Smith, T. E., Weggen, S., Das, P., McLendon, D. C., Ozols, V. V., Jessing, K. W., Zavitz, K. H., Koo, E. H., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18162 · Cited by 634 · see citing works

The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation

de Jonge, W. J., & Ulloa, L. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707264 · Cited by 627 · see citing works

Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia

Jack, C. R., Dickson, D. W., Parisi, J. E., Xu, Y. C., Cha, R. H., O’Brien, P. C., Edland, S. D., Smith, G. E., Boeve, B. F., Tangalos, E. G., et al. (2002) · Neurology · doi:10.1212/wnl.58.5.750 · Cited by 610 · see citing works

Bace1 modulates myelination in the central and peripheral nervous system

Hu, X., Hicks, C. W., He, W., Wong, P., Macklin, W. B., Trapp, B. D., & Yan, R. (2006) · Nature Neuroscience · doi:10.1038/nn1797 · Cited by 608 · see citing works

Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo

Bateman, R. J., Munsell, L. Y., Morris, J. C., Swarm, R., Yarasheski, K. E., & Holtzman, D. M. (2006) · Nature Medicine · doi:10.1038/nm1438 · Cited by 599 · see citing works

Molecular mimicry and immune‐mediated diseases

Oldstone, M. B. A. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.13.1255 · Cited by 594 · see citing works

Mutations of Tau Protein in Frontotemporal Dementia Promote Aggregation of Paired Helical Filaments by Enhancing Local β-Structure

von Bergen�, M., Barghorn, S., Li, L., Marx, A., Biernat, J., Mandelkow, E., & Mandelkow�, E. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105196200 · Cited by 590 · see citing works

Common mechanisms of amyloid oligomer pathogenesis in degenerative disease

Glabe, C. G. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.04.017 · Cited by 569 · see citing works

MUTANT GENES IN FAMILIAL ALZHEIMER'S DISEASE AND TRANSGENIC MODELS

Price, D. L., & Sisodia, S. S. (1998) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.21.1.479 · Cited by 568 · see citing works

Therapeutics for Alzheimer's Disease Based on the Metal Hypothesis

Bush, A. I., & Tanzi, R. E. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.001 · Cited by 566 · see citing works

Aβ42 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice

McGowan, E., Pickford, F., Kim, J., Onstead, L., Eriksen, J., Yu, C., Skipper, L., Murphy, M. P., Beard, J., Das, P., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.06.030 · Cited by 565 · see citing works

Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease

Fox, N. C., Black, R. S., Gilman, S., Rossor, M. N., Griffith, S. G., Jenkins, L., & Koller, M. (2005) · Neurology · doi:10.1212/01.wnl.0000159743.08996.99 · Cited by 550 · see citing works

Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines.

Wischik, C. M., Edwards, P. C., Lai, R. Y., Roth, M., & Harrington, C. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.11213 · Cited by 547 · see citing works

Linking Aβ and Tau in Late-Onset Alzheimer's Disease: A Dual Pathway Hypothesis

Small, S. A., & Duff, K. (2008) · Neuron · doi:10.1016/j.neuron.2008.11.007 · Cited by 546 · see citing works

Pin1-Dependent Prolyl Isomerization Regulates Dephosphorylation of Cdc25C and Tau Proteins

Zhou, X. Z., Kops, O., Werner, A., Lu, P., Shen, M., Stoller, G., Küllertz, G., Stark, M. J. R., Fischer, G. S., & Lu, K. P. (2000) · Molecular Cell · doi:10.1016/s1097-2765(05)00083-3 · Cited by 543 · see citing works

Clearing the brain's amyloid cobwebs

Selkoe, D. J. (2001) · Neuron · doi:10.1016/s0896-6273(01)00475-5 · Cited by 541 · see citing works

A Cholesterol-Lowering Drug Reduces β-Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease

Refolo, L. M., Pappolla, M. A., LaFrancois, J. J., Malester, B., Schmidt, S. D., Thomas-Bryant, T., Tint, G. S., Wang, R., Mercken, M. H., Petanceska, S. S., et al. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0422 · Cited by 521 · see citing works

Tau filament formation in transgenic mice expressing P301L tau

Götz, J., Chen, F., Barmettler, R., & Nitsch, R. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006531200 · Cited by 495 · see citing works

The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-β production

Pastorino, L., Sun, A., Lu, P.-J., Zhou, X. Z., Balastik, M., Finn, G., Wulf, G., Lim, J., Li, S.-H., Li, X., et al. (2006) · Nature · doi:10.1038/nature04543 · Cited by 487 · see citing works

Small assemblies of unmodified amyloid $beta;-protein are the proximate neurotoxin in Alzheimer?s disease

Klein, W. L., Stine, W. B., & Teplow, D. B. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.02.010 · Cited by 487 · see citing works

Cerebrospinal fluid protein biomarkers for Alzheimer’s disease

Blennow, K. (2004) · Neurotherapeutics · doi:10.1602/neurorx.1.2.213 · Cited by 487 · see citing works

The role of tau in neurodegeneration

Gendron, T. F., & Petrucelli, L. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-13 · Cited by 478 · see citing works

CHIP-Hsc70 Complex Ubiquitinates Phosphorylated Tau and Enhances Cell Survival

Shimura, H., Schwartz, D., Gygi, S. P., & Kosik, K. S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m305838200 · Cited by 469 · see citing works

Chaperones increase association of tau protein with microtubules

Dou, F., Netzer, W. J., Tanemura, K., Li, F., Hartl, F. U., Takashima, A., Gouras, G. K., Greengard, P., & Xu, H. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242720499 · Cited by 462 · see citing works

Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images

Fox, N. C., Crum, W. R., Scahill, R. I., Stevens, J. M., Janssen, J. C., & Rossor, M. N. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05408-3 · Cited by 455 · see citing works

γ-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia

Real, P. J., Tosello, V., Palomero, T., Castillo-Martín, M., Hernando, E., de Stanchina, E., Sulis, M. L., Barnes, K., Sawai, C. M., Homminga, I., et al. (2008) · Nature Medicine · doi:10.1038/nm.1900 · Cited by 443 · see citing works

Association of Low Plasma Aβ42/Aβ40 Ratios With Increased Imminent Risk for Mild Cognitive Impairment and Alzheimer Disease

Graff‐Radford, N. R., Crook, J. E., Lucas, J. A., Boeve, B. F., Knopman, D. S., Ivnik, R. J., Smith, G. E., Younkin, L. H., Petersen, R. C., & Younkin, S. G. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.354 · Cited by 441 · see citing works

Mutations causing neurodegenerative tauopathies

Goedert, M., & Jakes, R. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.08.007 · Cited by 438 · see citing works

Oligomers on the Brain: the Emerging Role of Soluble Protein Aggregates in Neurodegeneration.

Walsh, D. M., & Selkoe, D. J. (2004) · Protein and Peptide Letters · doi:10.2174/0929866043407174 · Cited by 428 · see citing works

M1 Receptors Play a Central Role in Modulating AD-like Pathology in Transgenic Mice

Caccamo, A., Oddo, S., Billings, L. M., Green, K. N., Martinez-Coria, H., Fisher, A., & LaFerla, F. M. (2006) · Neuron · doi:10.1016/j.neuron.2006.01.020 · Cited by 417 · see citing works

Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model

Zhang, B., Maiti, A., Shively, S., Lakhani, F., McDonald-Jones, G., Bruce, J., Lee, E. B., Xie, S. X., Joyce, S., Li, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406361102 · Cited by 413 · see citing works

Defects in Axonal Elongation and Neuronal Migration in Mice with Disrupted tau and map1b Genes

Takei, Y., Teng, J., Harada, A., & Hirokawa, N. (2000) · The Journal of Cell Biology · doi:10.1083/jcb.150.5.989 · Cited by 408 · see citing works

Accelerating Amyloid-β Fibrillization Reduces Oligomer Levels and Functional Deficits in Alzheimer Disease Mouse Models

Cheng, I. H.-J., Scearce-Levie, K. A., Legleiter, J. A., Palop, J. J., Gerstein, H., Bien‐Ly, N., Puolivaöli, J., Lesné, S., Ashe, K. H., Muchowski, P. J., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m701078200 · Cited by 403 · see citing works

Rational targeting of Notch signaling in cancer

Rizzo, P., Osipo, C., Foreman, K. E., Golde, T. E., Osborne, B. A., & Miele, L. (2008) · Oncogene · doi:10.1038/onc.2008.226 · Cited by 396 · see citing works

Small Molecule Inhibitors of α-Synuclein Filament Assembly

Masuda, M., Suzuki, N., Taniguchi, S., Oikawa, T., Nonaka, T., Iwatsubo, T., Hisanaga, S., Goedert, M., & Hasegawa, M. (2006) · Biochemistry · doi:10.1021/bi0600749 · Cited by 367 · see citing works

Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model

McLaurin, J., Kierstead, M. E., Brown, M. E., Hawkes, C. A., Lambermon, M. H. L., Phinney, A. L., Darabie, A. A., Cousins, J. E., French, J. E., Lan, M. F., et al. (2006) · Nature Medicine · doi:10.1038/nm1423 · Cited by 366 · see citing works

Aβ40 Inhibits Amyloid Deposition<i>In Vivo</i>

Kim, J., Onstead, L., Randle, S., Price, R., Smithson, L., Zwizinski, C., Dickson, D. W., Golde, T., & McGowan, E. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4849-06.2007 · Cited by 359 · cited 2× · see citing works

Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease

Masliah, E., Hansen, L., Adame, A., Crews, L. A., Bard, F., Lee, C., Seubert, P. A., Games, D., Kirby, L., & Schenk, D. (2005) · Neurology · doi:10.1212/01.wnl.0000148590.39911.df · Cited by 355 · see citing works

Inducible Expression of Tau Repeat Domain in Cell Models of Tauopathy

Khlistunova, I., Biernat, J., Wang, Y., Pickhardt, M., von Bergen�, M., Gažová, Z., Mandelkow�, E., & Mandelkow, E. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m507753200 · Cited by 350 · see citing works

Adipsin, a Biomarker of Gastrointestinal Toxicity Mediated by a Functional γ-Secretase Inhibitor

Searfoss, G. H., Jordan, W. H., Calligaro, D. O., Galbreath, E. J., Schirtzinger, L., Berridge, B. R., Gao, H. T., Higgins, M. A., May, P. C., & Ryan, T. P. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m307757200 · Cited by 336 · see citing works

Phase 2 Safety Trial Targeting Amyloid β Production With a γ-Secretase Inhibitor in Alzheimer Disease

Fleisher, A., Raman, R., Siemers, E., Becerra, L. M., Clark, C. M., Dean, R. A., Farlow, M. R., Galvin, J. E., Peskind, E. R., Quinn, J. F., et al. (2008) · Archives of Neurology · doi:10.1001/archneur.65.8.1031 · Cited by 332 · see citing works

Protein Kinase C-dependent α-Secretase Competes with β-Secretase for Cleavage of Amyloid-β Precursor Protein in the Trans-Golgi Network

Skovronsky, D., Moore, D. B., Milla, M. E., Doms, R. W., & Lee, V. M. ‐. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.4.2568 · Cited by 325 · see citing works

A γ‐secretase inhibitor decreases amyloid‐β production in the central nervous system

Bateman, R. J., Siemers, E. R., Mawuenyega, K. G., Wen, G., Browning, K. R., Sigurdson, W. C., Yarasheski, K. E., Friedrich, S. W., DeMattos, R. B., May, P. C., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21623 · Cited by 322 · see citing works

Amyloid β Protein Dimer-Containing Human CSF Disrupts Synaptic Plasticity: Prevention by Systemic Passive Immunization

Klyubin, I., Betts, V., Welzel, A. T., Blennow, K., Zetterberg, H., Wallin, A., Lemere, C. A., Cullen, W. K., Peng, Y., Wisniewski, T., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.5161-07.2008 · Cited by 321 · see citing works

A Textbook of Neuropathology

Weil, A. 1.-1. (1950) · Physical Therapy · doi:10.1093/ptj/30.5.213b · Cited by 320 · see citing works

18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease

Relkin, N. R., Szabo, P., Adamiak, B., Burgut, T., Monthé, C., Lent, R. W., Younkin, S. G., Younkin, L. H., Schiff, R. I., & Weksler, M. E. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.12.021 · Cited by 305 · see citing works

Biochemical detection of Aβ isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer’s disease

Golde, T. E., Eckman, C. B., & Younkin, S. G. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(00)00043-0 · Cited by 300 · see citing works

The Profile of Soluble Amyloid β Protein in Cultured Cell Media

Wang, R., Sweeney, D. A., Gandy, S., & Sisodia, S. S. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.50.31894 · Cited by 293 · see citing works

Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease

Siemers, E., Quinn, J. F., Kaye, J. A., Farlow, M. R., Porsteinsson, A. P., Tariot, P. N., Zoulnouni, P., Galvin, J. E., Holtzman, D. M., Knopman, D. S., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000198762.41312.e1 · Cited by 291 · see citing works

Accelerated filament formation from tau protein with specific FTDP‐17 missense mutations

Nacharaju, P., Lewis, J. M., Easson, C., Yen, S. H., Hackett, J., Hutton, M., & Yen, S.-H. C. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00294-x · Cited by 283 · see citing works

The role of Aβ42 in Alzheimer's disease

Younkin, S. G. (1998) · Journal of Physiology-Paris · doi:10.1016/s0928-4257(98)80035-1 · Cited by 282 · see citing works

Substrate-targeting γ-secretase modulators

Kukar, T. L., Ladd, T. B., Bann, M. A., Fraering, P. C., Narlawar, R., Maharvi, G. M., Healy, B., Chapman, R., Welzel, A. T., Price, R. W., et al. (2008) · Nature · doi:10.1038/nature07055 · Cited by 276 · see citing works

Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies

Luo, W., Dou, F., Rodina, A., Chip, S., Kim, J., Zhao, Q., Moulick, K., Aguirre, J., Wu, N. F., Greengard, P., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701055104 · Cited by 274 · see citing works

Inositol Stereoisomers Stabilize an Oligomeric Aggregate of Alzheimer Amyloid β Peptide and Inhibit Aβ-induced Toxicity

McLaurin, J., Golomb, R., Jurewicz, A., Antel, J. P., & Fraser, P. E. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m906994199 · Cited by 265 · see citing works

Genetic Neurodegenerative Diseases: The Human Illness and Transgenic Models

Price, D. L., Sisodia, S. S., & Borchelt, D. (1998) · Science · doi:10.1126/science.282.5391.1079 · Cited by 258 · see citing works

Interactions of Alzheimer amyloid‐β peptides with glycosaminoglycans

McLaurin, J., Franklin, T., Zhang, X., Deng, J., & Fraser, P. E. (1999) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1999.00957.x · Cited by 254 · see citing works

Deletion of the Ubiquitin Ligase CHIP Leads to the Accumulation, But Not the Aggregation, of Both Endogenous Phospho- and Caspase-3-Cleaved Tau Species

Dickey, C. A., Yue, M., Lin, W.-L., Dickson, D. W., Dunmore, J. H., Lee, W. C., Zehr, C., West, G., Cao, S., Clark, A. M. K., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0746-06.2006 · Cited by 248 · see citing works

Immunotherapy for Alzheimer’s disease: Key Symposium: Immunotherapy for Alzheimer’s disease

Morgan, D. (2011) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02315.x · Cited by 225 · see citing works

Muscle weakness, hyperactivity, and impairment in fear conditioning in tau-deficient mice

Ikegami, S. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00964-7 · Cited by 221 · see citing works

An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice

Corre, S. L., Klafki, H., Plesnila, N., Hübinger, G., Obermeier, A., Sahagún, H., Monse, B., Seneci, P., Lewis, J. M., Eriksen, J. L., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602913103 · Cited by 221 · see citing works

The Alzheimer‐like phosphorylation of tau protein reduces microtubule binding and involves Ser‐Pro and Thr‐Pro motifs

Gustke, N., Steiner, B., Mandelkow, E., Biernat, J., Meyer, H. E., Goedert, M., & Mandelkow, E. (1992) · FEBS Letters · doi:10.1016/0014-5793(92)80767-b · Cited by 219 · see citing works

Review: Modulating Factors in Amyloid-β Fibril Formation

McLaurin, J., Yang, D.-S., Yip, C. M., & Fraser, P. E. (2000) · Journal of Structural Biology · doi:10.1006/jsbi.2000.4289 · Cited by 217 · see citing works

Safety, Tolerability, and Changes in Amyloid β Concentrations After Administration of a γ-Secretase Inhibitor in Volunteers

Siemers, E., Skinner, M., Dean, R. A., Gonzales, C., Satterwhite, J. H., Farlow, M. R., NESS, D. K., & May, P. C. (2005) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000167360.27670.29 · Cited by 214 · see citing works

Transgenic models of Alzheimer’s disease: Learning from animals

Spires‐Jones, T. L., & Hyman, B. T. (2005) · NeuroRx · doi:10.1602/neurorx.2.3.423 · Cited by 209 · see citing works

β-Secretase (BACE) as a drug target for alzheimer’s disease

Vassar, R. J. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00157-6 · Cited by 209 · see citing works

The synaptic Aβ hypothesis of Alzheimer disease

Tanzi, R. E. (2005) · Nature Neuroscience · doi:10.1038/nn0805-977 · Cited by 206 · see citing works

The Tissue Plasminogen Activator-Plasminogen Proteolytic Cascade Accelerates Amyloid-β (Aβ) Degradation and Inhibits Aβ-Induced Neurodegeneration

Melchor, J. P., Pawlak, R., & Strickland, S. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-26-08867.2003 · Cited by 202 · see citing works

Ibuprofen reduces Aβ, hyperphosphorylated tau and memory deficits in Alzheimer mice

McKee, A. C., Carreras, I., Hossain, L., Ryu, H., Klein, W. L., Oddo, S., LaFerla, F. M., Jenkins, B. G., Kowall, N. W., & Dedeoglu, A. (2008) · Brain Research · doi:10.1016/j.brainres.2008.01.095 · Cited by 196 · see citing works

Textbook of neuropathology

Zimmerman, H. M. (1986) · Surgical Neurology · doi:10.1016/0090-3019(86)90249-1 · Cited by 194 · see citing works

Amyloid-β Peptide Remnants in AN-1792-Immunized Alzheimer's Disease Patients

Patton, R., Kalback, W. M., Esh, C. L., Kokjohn, T. A., Vickle, G. D. V., Luehrs, D. C., Kuo, Y., Lopez, J. C., Brune, D. C., Ferrer, I., et al. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.060269 · Cited by 192 · see citing works

Gleevec inhibits β-amyloid production but not Notch cleavage

Netzer, W. J., Dou, F., Cai, D., Veach, D. R., Jean, S., Li, Y., Bornmann, W. G., Clarkson, B., Xu, H., & Greengard, P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1534745100 · Cited by 192 · see citing works

Amyloid Accumulation and Pathogensis of Alzheimer’s Disease: Significance of Monomeric, Oligomeric and Fibrillar Aβ

Glabe, C. C. (2006) · Springer eBooks · doi:10.1007/0-387-23226-5_8 · Cited by 187 · see citing works

Prototype Alzheimer’s Disease Vaccine Using the Immunodominant B Cell Epitope from β-Amyloid and Promiscuous T Cell Epitope Pan HLA DR-Binding Peptide

Agadjanyan, M. G., Ghochikyan, A., Petrushina, I., Vasilevko, V., Movsesyan, N., Mkrtichyan, M., Saing, T., & Cribbs, D. H. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.3.1580 · Cited by 182 · see citing works

The Biology and Medicinal Chemistry of Epothilones

Wartmann, M., & Altmann, K. (2005) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1568011023354489 · Cited by 182 · see citing works

Alzheimer's Disease Neuroimaging Initiative: A one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition

Leow, A. D., Yanovsky, I., Parikshak, N., Hua, X., Lee, S., Toga, A. W., Jack, C. R., Bernstein, M. A., Britson, P. J., Gunter, J. L., et al. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.01.004 · Cited by 180 · see citing works

β-Secretase as a Therapeutic Target for Alzheimer’s Disease

Ghosh, A., Gemma, S., & Tang, J. J. N. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.007 · Cited by 175 · see citing works

A Decade of Tau Transgenic Animal Models and Beyond

Götz, J., Deters, N. A., Doldissen, A., Bokhari, L., Ke, Y. D., Wiesner, A., Schönrock, N., & Ittner, L. M. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00051.x · Cited by 174 · see citing works

In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer’s brain using the positron emission tomography molecular imaging probe 2-(1-{6-[(2-[18F]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile

Agdeppa, E. D., Kepe, V., Petri, A., Satyamurthy, N., Liu, J., Huang, S. C., Small, G. W., Cole, G. M., & Barrio, J. R. (2003) · Neuroscience · doi:10.1016/s0306-4522(02)00907-7 · Cited by 172 · see citing works

A cog in cognition: How the α7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits

Leiser, S. C., Bowlby, M. R., Comery, T. A., & Dunlop, J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.03.009 · Cited by 166 · see citing works

Orally available compound prevents deficits in memory caused by the Alzheimer amyloid‐β oligomers

Townsend, M., Cleary, J. P., Mehta, T., Hofmeister, J. J., Lesné, S., O‘Hare, E., Walsh, D. M., & Selkoe, D. J. (2006) · Annals of Neurology · doi:10.1002/ana.21051 · Cited by 166 · see citing works

Structure of tau protein and assembly into paired helical filaments

Friedhoff, P., von Bergen�, M., Mandelkow, E., & Mandelkow, E. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(00)00038-7 · Cited by 165 · see citing works

High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy

Rademakers, R., Melquist, S., Cruts, M., Theuns, J., Del-Favero, J., Poorkaj, P., Baker, M., Sleegers, K., Crook, R., De Pooter, T., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi361 · Cited by 164 · see citing works

HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites

Dickey, C. A., Dunmore, J., Lu, B., Wang, J., Lee, W. C., Kamal, A., Burrows, F., Eckman, C., Hutton, M., & Petrucelli, L. (2006) · The FASEB Journal · doi:10.1096/fj.05-5343fje · Cited by 160 · see citing works

A feasibility and tolerability study of lithium in Alzheimer's disease

Macdonald, A., Briggs, K., Poppe, M., Higgins, A. R., Velayudhan, L., & Lovestone, S. (2008) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1964 · Cited by 159 · see citing works

Etazolate, a neuroprotective drug linking GABAA receptor pharmacology to amyloid precursor protein processing

Marcade, M., Bourdin, J., Loiseau, N., Peillon, H., Rayer, A., Drouin, D., Schweighoffer, F., & Désiré, L. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05396.x · Cited by 155 · see citing works

Enhanced clearance of Aβ in brain by sustaining the plasmin proteolysis cascade

Jacobsen, J. S., Comery, T. A., Martone, R. L., Elokdah, H. M., Crandall, D. L., Oganesian, A., Aschmies, S., Kirksey, Y. M., Gonzales, C., Xu, J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710823105 · Cited by 146 · see citing works

Inhibition and Modulation of γ-Secretase for Alzheimer's Disease

Wolfe, M. S. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.010 · Cited by 143 · see citing works

Tau-Based Treatment Strategies in Neurodegenerative Diseases

Schneider, A., & Mandelkow�, E. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.006 · Cited by 142 · see citing works

Safety, Tolerability, and Effects on Plasma and Cerebrospinal Fluid Amyloid-&bgr; After Inhibition of &ggr;-Secretase

Siemers, E., Dean, R., Friedrich, S., Ferguson-Sells, L., Gonzales, C., Farlow, M., & May, P. (2007) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e31805b7660 · Cited by 140 · see citing works

In Vitro Polymerization of Tau Protein Monitored by Laser Light Scattering: Method and Application to the Study of FTDP-17 Mutants

Gamblin, T. C., King, M. E., Dawson, H. N., Vitek, M. P., Kuret, J., Berry, R. W., & Binder, L. I. (2000) · Biochemistry · doi:10.1021/bi000201f · Cited by 137 · see citing works

Development of AFFITOPE vaccines for Alzheimer's disease (AD) — From concept to clinical testing

Schneeberger, A., Mandler, M., Otava, O., Zauner, W., Mattner, F., & Schmidt, W. (2009) · The journal of nutrition health & aging · doi:10.1007/s12603-009-0070-5 · Cited by 130 · see citing works

Proteolytic mechanisms in amyloid-β metabolism: therapeutic implications for Alzheimer's disease

Vardy, E. R. L. C., Catto, A. J., & Hooper, N. M. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.08.004 · Cited by 130 · see citing works

Tau Phosphorylation, Tangles, and Neurodegeneration

Geschwind, D. H. (2003) · Neuron · doi:10.1016/s0896-6273(03)00681-0 · Cited by 129 · see citing works

The disordered neuronal cytoskeleton in Alzheimer's disease

Lee, V. M. ‐., & Trojanowski, J. Q. (1992) · Current Opinion in Neurobiology · doi:10.1016/0959-4388(92)90034-i · Cited by 129 · see citing works

Aβ42 immunization in Alzheimer's disease generates Aβ N-terminal antibodies

Lee, M., Bard, F., Johnson‐Wood, K., Lee, C., Hu, K., Griffith, S. G., Black, R. S., Schenk, D., & Seubert, P. A. (2005) · Annals of Neurology · doi:10.1002/ana.20592 · Cited by 129 · see citing works

An Overview of Phenserine Tartrate, A Novel Acetylcholinesterase Inhibitor for the Treatment of Alzheimers Disease

Greig, N. H., Sambamurti, K., Yu, Q.-S., Brossi, A. R., Bruinsma, G., & Lahiri, D. K. (2005) · Current Alzheimer Research · doi:10.2174/1567205054367829 · Cited by 122 · see citing works

The galvanization of β-amyloid in Alzheimer's disease

Bush, A. I., & Tanzi, R. E. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122249699 · Cited by 122 · see citing works

Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies

Nakashima, H., Ishihara, T., Suguimoto, S. P., Yokota, O., Oshima, E., Kugo, A., Terada, S., Hamamura, T., Trojanowski, J. Q., Lee, V. M. ‐., et al. (2005) · Acta Neuropathologica · doi:10.1007/s00401-005-1087-4 · Cited by 119 · see citing works

Transgenic mice expressing Alzheimer amyloid precursor proteins

Hsiao, K. (1998) · Experimental Gerontology · doi:10.1016/s0531-5565(98)00045-x · Cited by 119 · see citing works

Disease modifying therapy for AD?¹

Golde, T. E. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04211.x · Cited by 117 · see citing works

Immunotherapy Targeting Pathological Tau Protein in Alzheimer's Disease and Related Tauopathies

Sigurdsson, E. M. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-15202 · Cited by 116 · see citing works

Modeling Tau Polymerization in Vitro: A Review and Synthesis

Gamblin, T. C., Berry, R. W., & Binder, L. I. (2003) · Biochemistry · doi:10.1021/bi035722s · Cited by 114 · see citing works

Insights into the mechanisms of action of anti‐Aβ antibodies in Alzheimer's disease mouse models

Levites, Y., Smithson, L. A., Price, R. W., Dakin, R. S., Yuan, B., Sierks, M. R., Kim, J., McGowan, E., Kim Reed, D., Rosenberry, T. L., et al. (2006) · The FASEB Journal · doi:10.1096/fj.06-6463fje · Cited by 113 · see citing works

Discovery of Begacestat, a Notch-1-Sparing γ-Secretase Inhibitor for the Treatment of Alzheimer’s Disease

Mayer, S. C., Kreft, A. F., Harrison, B. L., Abou-Gharbia, M. A., Antane, M. M., Aschmies, S., Atchison, K. P., Chlenov, M. A., Cole, D. C., Comery, T. A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm801252w · Cited by 111 · see citing works

Stabilization of the Tau Exon 10 Stem Loop Alters Pre-mRNA Splicing

Donahue, C. P., Muratore, C., Wu, J. Y., Kosik, K. S., & Wolfe, M. S. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.c600143200 · Cited by 110 · see citing works

Natural human antibodies to amyloid beta peptide

Szabo, P., Relkin, N. R., & Weksler, M. E. (2008) · Autoimmunity Reviews · doi:10.1016/j.autrev.2008.03.007 · Cited by 107 · see citing works

The Development of Anti-Amyloid Therapy for Alzheimer???s Disease

Aisen, P. S. S. (2005) · CNS Drugs · doi:10.2165/00023210-200519120-00002 · Cited by 103 · see citing works

γ-Secretase Substrate Selectivity Can Be Modulated Directly via Interaction with a Nucleotide-binding Site

Fraering, P. C., Ye, W., LaVoie, M. J., Ostaszewski, B. L., Selkoe, D. J., & Wolfe, M. S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501368200 · Cited by 100 · see citing works

Nicotinic Receptor-Mediated Neuroprotection in Neurodegenerative Disease Models

Shimohama, S. (2009) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.32.332 · Cited by 99 · see citing works

The Aβ Hypothesis: Leading Us to Rationally-Designed Therapeutic Strategies for the Treatment or Prevention of Alzheimer Disease

Golde, T. E. (2006) · Brain Pathology · doi:10.1111/j.1750-3639.2005.tb00104.x · Cited by 98 · see citing works

Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases

Waldmeier, P. C., Bozyczko‐Coyne, D., Williams, M. J., & Vaught, J. L. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.06.031 · Cited by 95 · see citing works

The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation

Klunk, W. E., & Mathis, C. A. (2008) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3283168e1a · Cited by 92 · see citing works

Molecular Genetics of Chromosome 17 Tauopathies

HUTTON, M. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06906.x · Cited by 92 · see citing works

Mice as models: Transgenic approaches and Alzheimer's disease

Games, D., Buttini, M., Kobayashi, D. T., Schenk, D., & Seubert, P. A. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-9s316 · Cited by 91 · see citing works

Analysis of tauopathies with transgenic mice

Hutton, M., Lewis, J., Dickson, D., Yen, S.-H., & McGowan, E. (2001) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02123-2 · Cited by 91 · see citing works

Plasminogen activator activity is inhibited while neuroserpin is up‐regulated in the Alzheimer disease brain

Fabbro, S., & Seeds, N. W. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.05894.x · Cited by 89 · see citing works

The β‐amyloid protein of Alzheimer’s disease binds to membrane lipids but does not bind to the α7 nicotinic acetylcholine receptor

Small, D. H., Maksel, D., Kerr, M. L., Ng, J., Hou, X., Chu, C., Mehrani, H. A., Unabia, S. E., Azari, M. F., Loiacono, R. E., et al. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04444.x · Cited by 89 · see citing works

Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition

Kauwe, J. S. K., Cruchaga, C., Mayo, K., Fenoglio, C., Bertelsen, S. E., Nowotny, P., Galimberti, D., Scarpini, E. A., Morris, J. C., Fagan, A. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801227105 · Cited by 89 · see citing works

Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy

Boimel, M., Grigoriadis, N., Lourbopoulos, A., Touloumi, O., Rosenmann, D., Abramsky, O., & Rosenmann, H. (2009) · Journal of Neuropathology &amp; Experimental Neurology · doi:10.1097/nen.0b013e31819ac3cb · Cited by 86 · see citing works

1-(3′,4′-Dichloro-2-fluoro[1,1′-biphenyl]-4-yl)-cyclopropanecarboxylic Acid (CHF5074), a Novel γ-Secretase Modulator, Reduces Brain β-Amyloid Pathology in a Transgenic Mouse Model of Alzheimer’s Disease without Causing Peripheral Toxicity

Imbimbo, B. P., Giudice, E. D., Colavito, D., D’Arrigo, A., Carbonare, M. D., Villetti, G., Facchinetti, F., Volta, R., Pietrini, V., Baroc, M. F., et al. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.129007 · Cited by 84 · see citing works

ALS Drug Development: Reflections from the Past and a Way Forward

Aggarwal, S., & Cudkowicz, M. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.08.002 · Cited by 82 · see citing works

A roadmap for the prevention of dementia II: Leon Thal Symposium 2008

Khachaturian, Z. S. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.01.021 · Cited by 77 · see citing works

Shortage of human intravenous immunoglobulin—reasons and possible solutions

Bayry, J., Kazatchkine, M. D., & Kaveri, S. V. (2007) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0429 · Cited by 75 · see citing works

Wild-type Presenilin 1 Protects against Alzheimer Disease Mutation-induced Amyloid Pathology

Wang, R., Wang, B., He, W., & Zheng, H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512574200 · Cited by 73 · see citing works

Atorvastatin Therapy Lowers Circulating Cholesterol but not Free Radical Activity in Advance of Identifiable Clinical Benefit in the Treatment of Mild-to-Moderate AD

Sparks, D. L., Sabbagh, M., Connor, D. J., Lopez, J., Launer, L. J., Petanceska, S. S., Browne, P. J., Wassar, D., Johnson‐Traver, S., & Lochhead, J. J. (2005) · Current Alzheimer Research · doi:10.2174/1567205054367900 · Cited by 71 · see citing works

The therapeutic importance of understanding mechanisms of neuronal cell death in neurodegenerative disease

Golde, T. E. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-8 · Cited by 71 · see citing works

Absence of β-Amyloid Deposits After Immunization in Alzheimer Disease With Lewy Body Dementia

Bombois, S., Maurage, C., Gompel, M., Deramecourt, V., Mackowiak‐Cordoliani, M., Black, R. S., Lavielle, R., Delacourte, A., & Pasquier, F. (2007) · Archives of Neurology · doi:10.1001/archneur.64.4.583 · Cited by 69 · see citing works

Nicotinic receptor agonists and antagonists increase sAPPα secretion and decrease Aβ levels in vitro

Mousavi, M. T., & Hellström‐Lindahl, E. (2008) · Neurochemistry International · doi:10.1016/j.neuint.2008.12.001 · Cited by 60 · see citing works

Aβ Immunotherapy: Lessons Learned for Potential Treatment of Alzheimer’s Disease

Schenk, D. B., Seubert, P. A., Grundman, M., & Black, R. (2005) · Neurodegenerative Diseases · doi:10.1159/000090365 · Cited by 60 · see citing works

Progress from Alzheimer's tangles to pathological tau points towards more effective therapies now

Lee, V., & Trojanowski, J. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-9s328 · Cited by 57 · see citing works

Haplotype-based association analysis of the MAPT locus in Late Onset Alzheimer's disease

Mukherjee, O., Kauwe, J. S., Mayo, K., Morris, J. C., & Goate, A. (2007) · BMC Genetics · doi:10.1186/1471-2156-8-3 · Cited by 52 · see citing works

Possible Mechanisms of Action of NSAIDs and Related Compounds that Modulate γ - Secretase Cleavage

Kukar, T. L., & Golde, T. E. (2008) · Current Topics in Medicinal Chemistry · doi:10.2174/156802608783334042 · Cited by 50 · see citing works

Immunotherapy for Alzheimer’s disease

Morgan, D. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-9s348 · Cited by 50 · see citing works

The consequences of reducing expression of the α7 nicotinic receptor by RNA interference and of stimulating its activity with an α7 agonist in SH-SY5Y cells indicate that this receptor plays a neuroprotective role in connection with the pathogenesis of Alzheimer's disease

Qi, X., Nordberg, A. K., Xiu, J., & Guan, Z. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.04.002 · Cited by 49 · see citing works

BEYOND AMYLOID: The Next Generation of Alzheimer's Disease Therapeutics

Seabrook, G. R., Ray, W. J., Shearman, M. S., & Hutton, M. L. (2007) · Molecular Interventions · doi:10.1124/mi.7.5.8 · Cited by 48 · see citing works

Elevated brain scyllo‐inositol concentrations in patients with Alzheimer's disease

Griffith, H. R., den Hollander, J. A., Stewart, C. C., Evanochko, W. T., Buchthal, S. D., Harrell, L. E., ZAMRINI, E. Y., Brockington, J. C., & Marson, D. C. (2007) · NMR in Biomedicine · doi:10.1002/nbm.1132 · Cited by 48 · see citing works

Quantitative and Mechanistic Studies of A&amp;#946; Immunotherapy

Golde, T., Das, P., & Levites, Y. (2009) · CNS &amp; Neurological Disorders - Drug Targets · doi:10.2174/187152709787601830 · Cited by 46 · cited 5× · see citing works

Lithium Chloride Increases the Production of Amyloid-β Peptide Independently from Its Inhibition of Glycogen Synthase Kinase 3

Feyt, C., Kienlen‐Campard, P., Leroy, K., N’Kuli, F., Courtoy, P. J., Brion, J., & Octave, J. N. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501610200 · Cited by 46 · see citing works

Constitutive overactivation of protein kinase C in guinea pig brain increases α‐secretory APP processing without decreasing β‐amyloid generation

Roßner, S., Beck, M., Stahl, T., Mendla, K. D., Schliebs, R., & Bigl, V. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00211.x · Cited by 41 · see citing works

Identification of Novel Small Molecule Inhibitors of Amyloid Precursor Protein Synthesis as a Route to Lower Alzheimer’s Disease Amyloid-β Peptide

Utsuki, T., Yu, Q.-S., Davidson, D., Chen, D., Holloway, H. W., Brossi, A. R., Sambamurti, K., Lahiri, D. K., Greig, N. H., & Giordano, T. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.103309 · Cited by 39 · see citing works

Identification of Tau Stem Loop RNA Stabilizers

Donahue, C. P., Ni, J., Rozners, E., Glicksman, M. A., & Wolfe, M. S. (2007) · SLAS DISCOVERY · doi:10.1177/1087057107302676 · Cited by 38 · see citing works

Advances in gamma-secretase modulation.

Pissarnitski, D. A. (2007) · PubMed · Cited by 31 · see citing works

Regulated cleavage of the Alzheimer amyloid precursor protein: Molecular and cellular basis

Gandy, S., & Greengard, P. (1994) · Biochimie · doi:10.1016/0300-9084(94)90162-7 · Cited by 30 · see citing works

The Perils of Alzheimers Drug Development

Schneider, L. S. S., & Lahiri, D. K. (2009) · Current Alzheimer Research · doi:10.2174/156720509787313871 · Cited by 22 · see citing works

Attacking Amyloid

Kelly, J. W. (2005) · New England Journal of Medicine · doi:10.1056/nejmcibr044231 · Cited by 21 · see citing works

Phorbol esters affect multiple steps in beta-amyloid precursor protein trafficking and amyloid beta-protein production.

Koo, E. H. (1997) · PubMed · Cited by 19 · see citing works

Proteolytic Degradation of the Amyloid β-Protein: The Forgotten Side of Alzheimers Disease

Leissring, M. A. (2006) · Current Alzheimer Research · doi:10.2174/156720506779025206 · Cited by 17 · see citing works

Phorbol Esters Affect Multiple Steps in β-Amyloid Precursor Protein Trafficking and Amyloid β-Protein Production

Koo, E. H., & Greengard, P. (1997) · Molecular Medicine · doi:10.1007/bf03401673 · Cited by 16 · see citing works

Refining Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17

Boeve, B. F., & Hutton, M. (2008) · Archives of Neurology · doi:10.1001/archneur.65.4.460

The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics

Karran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188 · see citing works

Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer’s disease model

Sanchez, P. E., Zhu, L., Verret, L., Vossel, K. A., Orr, A. G., Cirrito, J. R., Devidze, N., Ho, K., Yu, G.-Q., Palop, J. J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121081109 · Cited by 638 · see citing works

Development of Multifunctional Molecules as Potential Therapeutic Candidates for Alzheimer’s Disease, Parkinson’s Disease, and Amyotrophic Lateral Sclerosis in the Last Decade

Savelieff, M. G., Nam, G., Kang, J., Lee, H. J., Lee, M., & Lim, M. H. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00138 · Cited by 603 · see citing works

Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift

Golde, T. E., Schneider, L. S., & Koo, E. H. (2011) · Neuron · doi:10.1016/j.neuron.2011.01.002 · Cited by 382 · see citing works

γ-Secretase inhibitors and modulators

Golde, T. E., Koo, E. H., Felsenstein, K. M., Osborne, B. A., & Miele, L. (2013) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2013.06.005 · Cited by 271 · see citing works

Inflammatory Cytokines and Alzheimer’s Disease: A Review from the Perspective of Genetic Polymorphisms

Su, F., Bai, F., & Zhang, Z. (2016) · Neuroscience Bulletin · doi:10.1007/s12264-016-0055-4 · Cited by 221 · see citing works

A Close Look at BACE1 Inhibitors for Alzheimer’s Disease Treatment

Das, B., & Yan, R. (2019) · CNS Drugs · doi:10.1007/s40263-019-00613-7 · Cited by 210 · see citing works

Structural basis of γ-secretase inhibition and modulation by small molecule drugs

Yang, G., Zhou, R., Guo, X., Yan, C., Lei, J., & Shi, Y. (2021) · Cell · doi:10.1016/j.cell.2020.11.049 · Cited by 189 · see citing works

Apolipoprotein E in Synaptic Plasticity and Alzheimer’s Disease: Potential Cellular and Molecular Mechanisms

Kim, J., Yoon, H., Basak, J., & Kim, J. (2014) · Molecules and Cells · doi:10.14348/molcells.2014.0248 · Cited by 141 · see citing works

Comment on “ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models.”

Price, A. R., Xu, G., Siemienski, Z. B., Smithson, L. A., Borchelt, D. R., Golde, T. E., & Felsenstein, K. M. (2013) · Science · doi:10.1126/science.1234089 · Cited by 138 · see citing works

Mercaptoacetamide-based class II HDAC inhibitor lowers Aβ levels and improves learning and memory in a mouse model of Alzheimer's disease

Sung, Y. M., Lee, T., Yoon, H., DiBattista, A. M., Song, J. M., Sohn, Y., Moffat, E. I., Turner, R. S., Jung, M., Kim, J., et al. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2012.10.005 · Cited by 137 · see citing works

Immunotherapy for Alzheimer‘s Disease: From Anti-β-Amyloid to Tau-Based Immunization Strategies

Panza, F., Frisardi, V., Solfrizzi, V., Imbimbo, B. P., Logroscino, G., Santamato, A., Greco, A., Seripa, D., & Pilotto, A. (2012) · Immunotherapy · doi:10.2217/imt.11.170 · Cited by 125 · see citing works

Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers

Golde, T. E. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01201-2 · Cited by 119 · see citing works

Robust amyloid clearance in a mouse model of Alzheimer’s disease provides novel insights into the mechanism of amyloid-β immunotherapy

Wang, A., Das, P., Switzer, R. C., Golde, T. E., & Jankowsky, J. L. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5077-10.2011 · Cited by 118 · see citing works

New perspectives on the role of tau in Alzheimer's disease. Implications for therapy

Medina, M., & Ávila, J. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.013 · Cited by 118 · see citing works

Progress and Developments in Tau Aggregation Inhibitors for Alzheimer Disease

Bulic, B., Pickhardt, M., & Mandelkow�, E. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm3017317 · Cited by 116 · see citing works

Active immunotherapy options for Alzheimer’s disease

Winblad, B. G., Graf, A., Riviere, M., Andreasen, N., & Ryan, J. M. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt237 · Cited by 100 · see citing works

Animal models of Alzheimer's disease and drug development

Laurijssens, B. E., Aujard, F., & Rahman, A. (2012) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2012.04.001 · Cited by 92 · see citing works

Identification and biology of α‐secretase

Vingtdeux, V., & Marambaud, P. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07477.x · Cited by 81 · see citing works

SCA8 RAN polySer protein preferentially accumulates in white matter regions and is regulated by eIF3F

Ayhan, F., Pérez, B., Shorrock, H. K., Zu, T., Báñez-Coronel, M., Reid, T. S., Furuya, H., Clark, H. B., Troncoso, J. C., Ross, C. A., et al. (2018) · The EMBO Journal · doi:10.15252/embj.201899023 · Cited by 72 · see citing works

Lipids in Amyloid-β Processing, Aggregation, and Toxicity

Morgado, I., & Garvey, M. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-17344-3_3 · Cited by 69 · see citing works

Amyloid and Alzheimer's Disease: Inside and Out

Tam, J. H. K., & Pasternak, S. (2012) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100013408 · Cited by 64 · see citing works

Strategies, Development, and Pitfalls of Therapeutic Options for Alzheimer's Disease

Haas, C. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110986 · Cited by 62 · see citing works

Computer-Aided Drug Design of β-Secretase, γ-Secretase and Anti-Tau Inhibitors for the Discovery of Novel Alzheimer’s Therapeutics

Mouchlis, V. D., Melagraki, G., Zacharia, L. C., & Afantitis, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030703 · Cited by 63 · see citing works

Ligand‐Based and Structure‐Based Investigation for Alzheimer’s Disease from Traditional Chinese Medicine

Liao, K., Chen, K., Lee, W., Sun, M.-F., Lee, C.-C., & Chen, C. Y. (2014) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2014/364819 · Cited by 57 · see citing works

Tau acts as a mediator for<scp>A</scp>lzheimer's disease‐related synaptic deficits

Liao, D., Miller, E. C., & Teravskis, P. J. (2014) · European Journal of Neuroscience · doi:10.1111/ejn.12504 · Cited by 53 · see citing works

Neuroprotective Activity of Asparagus racemosus Linn. Against Ethanol- Induced Cognitive Impairment and Oxidative Stress in Rats Brain: Auspicious for Controlling the Risk of Alzheimer’s Disease

Uddin, M. S., & Asaduzzaman, M. (2016) · Journal of Alzheimer’s Disease & Parkinsonism · doi:10.4172/2161-0460.1000245 · Cited by 51 · see citing works

Small-molecule drugs development for Alzheimer's disease

Yao, W., Yang, H., & Yang, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1019412 · Cited by 50 · see citing works

Secretory Sorting Receptors Carboxypeptidase E and Secretogranin III in Amyloid β‐Associated Neural Degeneration in A lzheimer's Disease

Plá, V., Paco, S., Ghézali, G., Ciria, V., Pozas, E., Ferrer, I., & Aguado, F. (2012) · Brain Pathology · doi:10.1111/j.1750-3639.2012.00644.x · Cited by 50 · see citing works

From a mouse: systematic analysis reveals limitations of experiments testing interventions in Alzheimer's disease mouse models

Egan, K. J., Vesterinen, H. M., Beglopoulos, V., Sena, E. S., & Macleod, M. R. (2016) · Evidence-based Preclinical Medicine · doi:10.1002/ebm2.15 · Cited by 47 · see citing works

Alzheimer's disease vaccine development: A new strategy focusing on immune modulation

Marciani, D. J. (2015) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2015.08.008 · Cited by 46 · see citing works

Alzheimer's disease: brain expression of a metabolic disorder?

Merlo, S., Spampinato, S. F., Canonico, P. L., Copani, A., & Sortino, M. A. (2010) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2010.05.005 · Cited by 47 · see citing works

Rational heterodoxy: Cholesterol reformation of the amyloid doctrine

Castello, M. A., & Soriano, S. (2012) · Ageing Research Reviews · doi:10.1016/j.arr.2012.06.007 · Cited by 44 · see citing works

siRNA Therapeutics: Future Promise for Neurodegenerative Diseases

Amiri, A., Barreto, G. E., Sathyapalan, T., & Sahebkar, A. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210402104054 · Cited by 45 · see citing works

GPR3 Stimulates Aβ Production via Interactions with APP and β-Arrestin2

Nelson, C. D., & Sheng, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074680 · Cited by 42 · see citing works

Inhibiting mtDNA‐STING‐NLRP3 / IL ‐1β axis‐mediated neutrophil infiltration protects neurons in Alzheimer's disease

Xia, X., He, X., Zhao, T., Yang, J., Bi, Z., Fu, Q., Liu, J., Ao, D., Wei, Y., & Wei, X. (2023) · Cell Proliferation · doi:10.1111/cpr.13529 · Cited by 38 · see citing works

The Effects of Soluble A.β Oligomers on Neurodegeneration in Alzheimer's Disease

Brouillette, J. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990498 · Cited by 38 · see citing works

Tools of the Trade: Investigations into Design Strategies of Small Molecules to Target Components in Alzheimer's Disease

Derrick, J. S., & Lim, M. H. (2015) · ChemBioChem · doi:10.1002/cbic.201402718 · Cited by 38 · see citing works

Animal Models for Alzheimer’s Disease and Frontotemporal Dementia: A Perspective

Götz, J., & Götz, N. N. (2009) · ASN NEURO · doi:10.1042/an20090042 · Cited by 37 · see citing works

NGP 555, a γ‐secretase modulator, lowers the amyloid biomarker, Aβ 42, in cerebrospinal fluid while preventing Alzheimer's disease cognitive decline in rodents

Kounnas, M. Z., Lane‐Donovan, C., Nowakowski, D. W., Herz, J., & Comer, W. T. (2016) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.09.003 · Cited by 37 · see citing works

Levetiracetam alleviates cognitive decline in Alzheimer’s disease animal model by ameliorating the dysfunction of the neuronal network

Zheng, X., Lv, Y.-D., Jin, F., Zhang, H., Wu, X., Zhu, J., & Ruan, Y. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.888784 · Cited by 36 · see citing works

Transient pharmacologic lowering of Aβ production prior to deposition results in sustained reduction of amyloid plaque pathology

Das, P., Verbeeck, C., Minter, L. M., Chakrabarty, P., Felsenstein, K. M., Kukar, T. L., Maharvi, G. M., Fauq, A. H., Osborne, B. A., & Golde, T. E. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-39 · Cited by 35 · see citing works

Retention in Endoplasmic Reticulum 1 (RER1) Modulates Amyloid-β (Aβ) Production by Altering Trafficking of γ-Secretase and Amyloid Precursor Protein (APP)

Park, H., Shabashvili, D. E., Nekorchuk, M. D., Shyqyriu, E., Jung, J. I., Ladd, T. B., Moore, B. D., Felsenstein, K. M., Golde, T. E., & Kim, S.-H. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.418442 · Cited by 34 · see citing works

Advances with RNA interference in Alzheimer’s disease research

Yuan, W., Chen, S., Ge, X., Chen, Y., Lu, N., & Liu, Z. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s40229 · Cited by 33 · see citing works

SPON1 Can Reduce Amyloid Beta and Reverse Cognitive Impairment and Memory Dysfunction in Alzheimer’s Disease Mouse Model

Park, S. Y., Kang, J. Y., Lee, T., Nam, D., Jeon, C., & Kim, J. B. (2020) · Cells · doi:10.3390/cells9051275 · Cited by 32 · see citing works

Rapamycin inhibits lipopolysaccharide-induced neuroinflammation in vitro and in vivo

Mengke, N.-S., Hu, B., Han, Q., Deng, Y., Fang, M., Xie, D., Li, A., & Zeng, H. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5883 · Cited by 30 · see citing works

Alzheimer’s Disease: Characterization of the Brain Sites of the Initial Tau Cytoskeletal Pathology Will Improve the Success of Novel Immunological Anti-Tau Treatment Approaches

Rüb, U., Stratmann, K., Heinsen, H., Seidel, K., Bouzrou, M., & Korf, H. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161102 · Cited by 30 · see citing works

Changing Perspectives on Alzheimer's Disease: Thinking Outside the Amyloid Box

D’Alton, S., & George, D. R. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110089 · Cited by 29 · see citing works

Dianxianning improved amyloid β-induced pathological characteristics partially through DAF-2/DAF-16 insulin like pathway in transgenic C. elegans

Zhi, D., Wang, D., Yang, W., Duan, Z., Zhu, S., Dong, J., Wang, N., Wang, N., Fei, D., Zhang, Z., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-11628-9 · Cited by 29 · see citing works

Post-Translational Modifications of BACE1 in Alzheimer's Disease

Wen, W., Li, P., Liu, P., Xu, S., Wang, F., & Huang, J. H. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210121163224 · Cited by 30 · see citing works

Molecular Neurobiology of Depression: PET Findings on the Elusive Correlation with Symptom Severity

Smith, D. F., & Jakobsen, S. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00008 · Cited by 25 · see citing works

Evolution of Neurodegeneration

Cookson, M. (2012) · Current Biology · doi:10.1016/j.cub.2012.07.008 · Cited by 25 · see citing works

Complex Relationships between Substrate Sequence and Sensitivity to Alterations in γ-Secretase Processivity Induced by γ-Secretase Modulators

Jung, J. I., Ran, Y., Cruz, P. E., Rosario, A. M., Ladd, T. B., Kukar, T. L., Koo, E. H., Felsenstein, K. M., & Golde, T. E. (2014) · Biochemistry · doi:10.1021/bi401521t · Cited by 22 · see citing works

Investigational Drug Treatments for Triple-Negative Breast Cancer

Damaskos, C., Garmpis, N., Garmpi, A., Nikolettos, K., Sarantis, P., GEORGAKOPOULOU, V. E., Nonni, A., Schizas, D., Antoniou, E., Karamouzis, M. V., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11070652 · Cited by 20 · see citing works

Sodium tanshinone IIA sulfonate protects against Aβ‐induced cell toxicity through regulating Aβ process

Zhang, D., Lu, X., He, S., Li, W., Ao, R., Leung, F. C.-Y., Zhang, Z., Chen, Q., & Zhang, S. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15006 · Cited by 20 · see citing works

Alum and Squalene-Oil-in-Water Emulsion Enhance the Titer and Avidity of Anti-Aβ Antibodies Induced by Multimeric Protein Antigen (1–11)E2, Preserving the Igg1-Skewed Isotype Distribution

Mantile, F., Trovato, M., Santoni, A., Barba, P., Ottonello, S., Berardinis, P. D., & Prisco, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101474 · Cited by 19 · see citing works

Prostaglandin EP2 receptor antagonist ameliorates neuroinflammation in a two-hit mouse model of Alzheimer’s disease

Banik, A., Amaradhi, R., Lee, D. D., Sau, M., Wang, W., Dingledine, R. J., & Ganesh, T. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02297-7 · Cited by 18 · see citing works

Racial Differences in Alzheimer’s Disease Specialist Encounters Are Associated with Usage of Molecular Imaging and Dementia Medications: An Enterprise-Wide Analysis Using i2b2

Murchison, C., Kennedy, R., McConathy, J., & Roberson, E. D. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200796 · Cited by 17 · see citing works

NeuroRDF: semantic integration of highly curated data to prioritize biomarker candidates in Alzheimer's disease

Iyappan, A., Kawalia, S. B., Raschka, T., Hofmann-Apitius, M., & Senger, P. (2016) · Journal of Biomedical Semantics · doi:10.1186/s13326-016-0079-8 · Cited by 13 · see citing works

A dual magnetic resonance imaging/fluorescent contrast agent for Cathepsin‐D detection

Ta, R. M., Suchý, M., Tam, J. H. K., Li, A. X., Martínez‐Santiesteban, F., Scholl, T. J., Hudson, R. H. E., Bartha, R., & Pasternak, S. (2012) · Contrast Media & Molecular Imaging · doi:10.1002/cmmi.1502 · Cited by 17 · see citing works

Bexarotene Impairs Cognition and Produces Hypothyroidism in a Mouse Model of Down Syndrome and Alzheimer’s Disease

Vidal, V., Puente, A., García-Cerro, S., Unzueta, M. T. G., Rueda, N., Riancho, J., & Martínez-Cué, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.613211 · Cited by 12 · see citing works

Boswellic Acids as Promising Leads in Drug Development against Alzheimer’s Disease

Haghaei, H., Soltani, S., Hosseini, S. R. A., Rashidi, M., & Karima, S. (2020) · Pharmaceutical Sciences · doi:10.34172/ps.2020.25 · Cited by 16 · see citing works

Protective Effects of Dietary Supplementation with a Combination of Nutrients in a Transgenic Mouse Model of Alzheimer’s Disease

Wang, S., Cu, Y., Wang, C., Xie, W., Ma, L., Zhu, J., Zhang, Y., Dang, R., Wang, D., Wu, Y., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143135 · Cited by 15 · see citing works

Recent Trends in Active and Passive Immunotherapies of Alzheimer’s Disease

Alshamrani, M. (2023) · Antibodies · doi:10.3390/antib12020041 · Cited by 16 · see citing works

Glaucoma and Alzheimer’s Disease in the Elderly

Bizrah, M., Guo, L., & Cordeiro, M. F. (2011) · Aging Health · doi:10.2217/ahe.11.51 · Cited by 14 · see citing works

Camptothecin and its Analogs Reduce Amyloid-β Production and Amyloid-β42-Induced IL-1β Production

Wang, J., Shi, Z., Zhang, M., Xin, G.-Z., Pang, T., Zhou, P. H., Chen, J., Qi, L., Yang, H. Q., Xu, X., et al. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140078 · Cited by 12 · see citing works

Novel disease-modifying therapeutics for the treatment of Alzheimer’s disease

Léger, G. C., & Massoud, F. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2013.811237 · Cited by 10 · see citing works

Modeling of age‐dependent amyloid accumulation and γ‐secretase inhibition of soluble and insoluble Aβ in a transgenic mouse model of amyloid deposition

PARKINSON, J. R., Ploeger, B. A., Appelkvist, P., Bogstedt, A., Bergstedt, K. D., Eketjäll, S., & Visser, S. A. G. (2013) · Pharmacology Research & Perspectives · doi:10.1002/prp2.12 · Cited by 9 · see citing works

Optimizing Diagnosis and Management in mild-to-moderate Alzheimer’s Disease

Galvin, J. E. (2012) · Neurodegenerative Disease Management · doi:10.2217/nmt.12.21 · Cited by 9 · see citing works

NGP 555, a γ‐secretase modulator, shows a beneficial shift in the ratio of amyloid biomarkers in human cerebrospinal fluid at safe doses

Kounnas, M. Z., Durakoglugil, M. S., Herz, J., & Comer, W. T. (2019) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.06.006 · Cited by 9 · see citing works

Combination of Aβ clearance and neurotrophic factors as a potential treatment for Alzheimer’s disease

Lin, L.-F., Liao, M., Xue, X., Zhang, W., Yan, L., Cai, L., Zhou, X., Zhou, X., & Luo, H. (2012) · Neuroscience Bulletin · doi:10.1007/s12264-012-1287-6 · Cited by 10 · see citing works

Combination of Aβ Suppression and Innate Immune Activation in the Brain Significantly Attenuates Amyloid Plaque Deposition

Verbeeck, C., Carrano, A., Chakrabarty, P., Jankowsky, J. L., & Das, P. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.08.010 · Cited by 8 · see citing works

Vimentin Fragmentation and Its Role in Amyloid-Beta Plaque Deposition in Alzheimer’s Disease

Zhang, L., Wang, J., Yan, Y., Xiang, L., Zhai, X., Cai, L., Sun, Z., Pi, M., Xiong, Q., Zhou, H., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26072857 · Cited by 7 · see citing works

Early intervention using long-term rhythmic pulsed magnetic stimulation alleviates cognitive decline in a 5xFAD mouse model of Alzheimer's disease

Wang, X., Wang, Q., Wang, X., Zhao, H., Zhao, C., Jiao, Y., Shi, H., Chen, C., Chen, H., Wang, P., et al. (2024) · Experimental Neurology · doi:10.1016/j.expneurol.2024.115002 · Cited by 6 · see citing works

Exploring Heparan Sulfate Proteoglycans as Mediators of Human Mesenchymal Stem Cell Neurogenesis

Petersen, S. I., Okolicsanyi, R. K., & Haupt, L. M. (2024) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-024-01463-8 · Cited by 6 · see citing works

SIRT1: A Novel Way to Target Tau?

Futch, H. S., & Croft, C. L. (2018) · Journal of Neuroscience · doi:10.1523/jneurosci.1201-18.2018 · Cited by 6 · see citing works

Alzheimer Hastalığı Tedavisindeki Güncel Yaklaşımlar

ODABAŞI, M. D., & KÜÇÜKKILINÇ, Z. T. T. (2021) · Hacettepe University Journal of the Faculty of Pharmacy · doi:10.52794/hujpharm.955421 · Cited by 3 · see citing works

Molecular Targets of Alzheimer’s Disease Treatment

Bharathi, K., Souza, F. J. D., Chandana, C., & Vishwanath, B. A. (2025) · Research Journal of Pharmacology and Pharmacodynamics · doi:10.52711/2321-5836.2025.00020 · Cited by 2 · see citing works

Generation of a new transgenic mouse model for assessment of tau gene silencing therapies

Fromholt, S., Reitano, C., Brown, H. H., Lewis, J. M., & Borchelt, D. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0202-1 · Cited by 2 · see citing works

Filipin Levels as Potential Predictors of Alzheimer’s Disease Risk

Castello, M. A., Howard, K. D., Castaneda, A. J., & Soriano, S. (2014) · Advances in Alzheimer s Disease · doi:10.4236/aad.2014.33013 · Cited by 2 · see citing works

Apolipoprotein E4: A Risk Factor for Successful Cognitive Aging

Kwon, O. D. (2016) · Dementia and Neurocognitive Disorders · doi:10.12779/dnd.2016.15.3.61 · Cited by 1 · see citing works

Assessment of In-House Natural Product and Synthetic Compound Libraries Based on In vitro Inhibition of Cholinesterases

Järvinen, P. P. (2011) · Työväentutkimus Vuosikirja

Active immunotherapy options for Alzheimer's

Winblad, B. G., Graf, A., Riviere, M., Andreasen, N., & Ryan, J. M. (2014)

Therapeutic Targeting of Aβ42

Golde, T. E., Lessard, C. B., & Ran, Y. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00005-8

Microglial Mitophagy and Neurodegenerative Disorders

Oyindamola, E. A., Agyemang, M. K., Owusu-Sarfo, J., Yeboah, K. O., & Osafo, N. (2020) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-7998-1317-0.ch004

Adipokines and Alzheimer's Disease

Sortino, M. A., Merlo, S., & Spampinato, S. F. (2011) · Royal Society of Chemistry eBooks · doi:10.1039/bk9781849733434-00130

Pathological chronology and pathological biochemistry: The beginning of the beginning

Saido, T. C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-28979-8.00022-x

Alzheimer Hastalığı Tedavisindeki Güncel Yaklaşımlar

ODABAŞI, M. D., & KÜÇÜKKILINÇ, Z. T. T. (2021) · DergiPark (Istanbul University)

Chronic stress and glucocorticoid actions in brain plasticity and Tau pathology

Dioli, C. (2021) · theses.fr (ABES) · doi:10.70675/b812791ezcc0az4036zb746z0d9b5daacfab

BindingDB Entry 50042999: Progress and developments in tau aggregation inhibitors for Alzheimer disease.

BindingDB (2014) · UC San Diego · doi:10.7270/q2ht2qqd

PL‐02‐03: Obstacles to translating preclinical advances into successful therapies for Alzheimer's disease

Golde, T. E. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.05.260

Targets and Strategies Toward the Development of Alzheimer Therapeutics

Wolfe, M. S. (2016) · Topics in medicinal chemistry · doi:10.1007/7355_2016_14 · Cited by 1 · see citing works

An effective treatment for Alzheimer's disease must consider both amyloid and tau

Lansdall, C. J. (2014) · Bioscience Horizons The International Journal of Student Research · doi:10.1093/biohorizons/hzu002 · Cited by 45 · see citing works

Targeting tau in Alzheimer’s Disease: rationale, approach and challenges

Aslanyan, A., Foiani, M. S., Giovannucci, T. A., McDade, E., Duff, K., Mummery, C. J., Schöll, M., Wildsmith, K. R., & Paterson, R. W. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00925-5 · Cited by 10 · see citing works

Tau-Directed Therapies for Alzheimer’s Disease and Other Tauopathies

(2013) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9781608057221113010006